BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36125673)

  • 1. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
    Hamidianjahromi A; Tritos NA
    Rev Endocr Metab Disord; 2022 Oct; 23(5):1089-1099. PubMed ID: 36125673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MANAGEMENT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry?
    Barake M; Klibanski A; Tritos NA
    Eur J Endocrinol; 2018 Dec; 179(6):R287-R296. PubMed ID: 30324793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors.
    De Sousa SMC; Baranoff J; Rushworth RL; Butler J; Sorbello J; Vorster J; Thompson T; McCormack AI; Inder WJ; Torpy DJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31580439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.
    Beccuti G; Guaraldi F; Natta G; Cambria V; Prencipe N; Cicolin A; Montanaro E; Lopiano L; Ghigo E; Zibetti M; Grottoli S
    J Endocrinol Invest; 2021 Aug; 44(8):1699-1706. PubMed ID: 33314003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
    Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
    Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.
    Bancos I; Nannenga MR; Bostwick JM; Silber MH; Erickson D; Nippoldt TB
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):863-8. PubMed ID: 24274365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
    Ioachimescu AG; Fleseriu M; Hoffman AR; Vaughan Iii TB; Katznelson L
    Eur J Endocrinol; 2019 Jan; 180(1):31-40. PubMed ID: 30400048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
    Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.
    Barake M; Evins AE; Stoeckel L; Pachas GN; Nachtigall LB; Miller KK; Biller BM; Tritos NA; Klibanski A
    Pituitary; 2014 Apr; 17(2):150-6. PubMed ID: 23504371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.
    Martinkova J; Trejbalova L; Sasikova M; Benetin J; Valkovic P
    Clin Neuropharmacol; 2011; 34(5):179-81. PubMed ID: 21738024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study.
    Ke X; Wang L; Chen M; Liu S; Yu N; Duan L; Gong F; Zhu H
    BMC Endocr Disord; 2022 Apr; 22(1):97. PubMed ID: 35410236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review.
    Hamblin R; Karavitaki N
    Arch Med Res; 2023 Dec; 54(8):102910. PubMed ID: 37985276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.
    Thondam SK; Alusi S; O'Driscoll K; Gilkes CE; Cuthbertson DJ; Daousi C
    Clin Neuropharmacol; 2013; 36(5):170-2. PubMed ID: 24045609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas.
    Hinojosa-Amaya JM; Johnson N; González-Torres C; Varlamov EV; Yedinak CG; McCartney S; Fleseriu M
    Front Endocrinol (Lausanne); 2020; 11():579606. PubMed ID: 33193096
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
    De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
    Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature.
    Sanjan G; Das L; Ahuja CK; Dhandapani S; Sachdeva N; Grover S; Dutta P
    Neurol India; 2023; 71(1):107-112. PubMed ID: 36861582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.
    Almanzar S; Zapata-Vega MI; Raya JA
    Psychosomatics; 2013; 54(4):387-91. PubMed ID: 23261076
    [No Abstract]   [Full Text] [Related]  

  • 19. Impulse Control and Related Disorders in Parkinson's Disease.
    Weintraub D; Claassen DO
    Int Rev Neurobiol; 2017; 133():679-717. PubMed ID: 28802938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
    Celik E; Ozkaya HM; Poyraz BC; Saglam T; Kadioglu P
    Endocrine; 2018 Dec; 62(3):692-700. PubMed ID: 30206771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.